Phase 3 ECHO Trial: Study Design and Efficacy Data

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Three patients treated at the first dose level of BAFF CAR-T cells experienced minimal adverse effects in a phase 1 study.

Leaders from the lymphoma space highlight the importance of mentorship in establishing their careers and impart advice to women looking to advance theirs.

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Phase 3 data show that nivolumab/AVD may also reduce long-term toxicities vs brentuximab vedotin/AVD in advanced Hodgkin lymphoma.